3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
5
Liposarcoma
3
Inflammatory Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Ketosis
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-negative Metastatic Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
eribulin
×
1 year
×
Clear all
No trials found.